Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

Researchers from NDORMS, the Department of Oncology and Wellcome Centre for Human Genetics attend the Big Bang Fair 2018 to inspire the next generation of scientists.

Last week three departments and units across the Medical Sciences Division - NDORMS, the Department of Oncology, and the Wellcome Centre for Human Genetics - attended the Big Bang Science Fairthe largest celebration of science, technology, engineering and maths (STEM) for young people in the UK. With an audience aged mainly 7-19, the event was a fantastic opportunity to educate and inspire the next generation of scientists. 

A variety of activities were used to engage visitors with the fantastic world of medical science. Researchers from the Kennedy Institute of Rheumatology (NDORMS) used a giant model of a gut wall, complete with magnetic plush bacteria and viruses, to talk about the microbes in our digestive tract and how important they are to our health, while children were also offered the chance to try keyhole surgery on a model knee. 

DNA Damage 2.jpg

'DNA Damage Wool Bags' from the Wellcome Centre for Human Genetics offered an insight into the size and complexity of our DNA; visitors had 30 seconds to rummage through miles of DNA wool to find the different kinds of damage DNA undergoes. A researcher from the Oxford Vaccine Group (Department of Paediatrics) also helped children to understand the complexity of DNA by showing them how to decode strings of DNA sequences to uncover the hidden messages. 

Finally, Oncology researchers were on hand with chocolate CT scans to teach visitors about the part X-rays and CT scans can play in diagnosing cancer. 

Oncology.jpg

Congratulations to all researchers who took part! 

See some highlights from the Big Bang Fair

Find out more about Public Engagement with Research across the Medical Sciences Division

Similar stories

Alternating vaccines trial expands to include two additional vaccines

Clinical Trials Coronavirus COVID-19 General

Researchers running the Com-Cov study, launched in February to investigate alternating doses of the Oxford-AstraZeneca vaccine and the Pfizer vaccine, have today announced that the programme will be extended to include the Moderna and Novavax vaccines in a new study.

Oxford medical students launch flagship raffle in aid of NHS heroes and lifesaving medical equipment

General

Tingewick, a society formed of medical students from Oxford University, are hosting a virtual charity raffle. With over 70 amazing prizes, ranging from Truck festival tickets to restaurant vouchers to bags of books and even a bike, the raffle is an exciting way to celebrate lockdown lifting by supporting many wonderful Oxfordshire businesses whilst raising lots of money for charity.

UK and EU regulators conclude benefits of vaccination continue to outweigh the risks

Coronavirus COVID-19 General

Today, the medical regulators in the UK and Europe have announced their conclusions from their reviews of very rare cases of unusual blood clots in people who have received the Oxford-AstraZeneca coronavirus vaccine.

Link between COVID-19 infection and subsequent mental health and neurological conditions found

Coronavirus COVID-19 General Research

One in three COVID-19 survivors received a neurological or psychiatric diagnosis within six months of infection with the SARS-CoV-2 virus, an observational study of more than 230,000 patient health records published in The Lancet Psychiatry journal estimates. The study looked at 14 neurological and mental health disorders.

New national study of long-term impacts of debilitating lung damage from COVID-19

Coronavirus COVID-19 General Research

A new national study will investigate the long-term effects of lung inflammation and scarring from COVID-19. The study, launched with £2 million of funding from UK Research and Innovation (UKRI), aims to develop treatment strategies and prevent disability.